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ow High-Density
ipoprotein Cholesterol
nd Chronic Disease Risk
arker or Causal?*
ennifer G. Robinson, MD, MPH
owa City, Iowa
umerous epidemiological studies have demonstrated a
trong inverse relationship between high-density lipoprotein
holesterol (HDL-C) and the risk of cardiovascular events
1). In this issue of the Journal, a meta-analysis of lipid-
odifying drug trials has extended the harmful association
f low HDL-C to increased risk of cancer (2). Does low
DL-C cause cancer (or even cardiovascular disease for
hat matter)? Evidence of causality would suggest that
nterventions to increase HDL-C could decrease the risk of
he 2 most important causes of morbidity and mortality in
he U.S. (3). Short of randomized clinical trial data as proof
f causality, epidemiologists have developed several criteria
or determining causality from observational data. Evidence
or a causal relationship between HDL-C and cancer or
ardiovascular disease is reviewed in the following text and
ummarized in Table 1.
See page 2846
emporality
id the low HDL-C levels predate the disease or did the
isease cause low HDL-C levels (also known as reverse
ausality)? For example, evidence of reverse causality has
een found for low total cholesterol levels associated with an
ncreased cancer risk. A recent analysis of the ATBC
Alpha-Tocopherol, Beta-Carotene Cancer) Prevention
ohort of 29,093 male Finnish smokers followed for 18
ears found that the inverse association between total
holesterol and cancer entirely disappeared when cancer
ases diagnosed during the first 9 years of follow-up were
xcluded (4). Another large cohort study in men found that
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of Epidemiology and Medicine, Lipid Research Clinic,
niversity of Iowa, Iowa City, Iowa. In the past year, Dr. Robinson’s institution hase
eceived grants from Abbott, Aegerion, Bristol-Myers Squibb, Daiichi-Sankyo,
laxoSmithKline, Hoffman-La Roche, Merck, and Merck Schering-Plough.otal cholesterol levels started to decrease approximately
years before cancer diagnosis (5). Therefore, reverse
ausality explains the relationship to low low-density li-
oprotein (LDL) cholesterol, which largely constitutes total
holesterol, previously described by this group in the Journal
6). In contrast, reverse causality does not appear to explain
he relationship between low HDL-C and cancer. In the
TBC study, the relationship between low HDL-C and
ncreased cancer risk (highest to lowest quintile, relative
isk: 0.89; 95% confidence interval: 0.83 to 0.97, p for
rend  0.01) persisted after excluding cancer cases diag-
osed within 12 years of study entry, and there is no
vidence of reverse causality for HDL-C and cardiovascular
isease. In the Framingham study, low HDL-C at baseline
redicts increased cardiovascular risk 30 years later (7).
ose Response
n their meta-analysis, Jafri et al. (2) report a 36% lower
ancer rate for each 10-mg/dl increase in HDL-C. The
TBC investigators also found evidence of a dose-response
elationship, although a less robust one, of an approximately
% lower cancer rate per 10-mg/dl increase in HDL-C up
o a level of 55 mg/dl (4). For cardiovascular disease, each
-mg/dl higher increment in HDL-C is associated with a
% to 3% decrement in cardiovascular risk (1).
iological Plausibility
he protective cardiovascular effects of high-density li-
oprotein (HDL) are largely attributed to reverse choles-
erol transport of cholesterol from lipid-laden macrophages
n peripheral tissues to the liver for catabolism and excretion
nto bile (8). HDL may have other antiatherosclerotic, as
ell as anticancer, effects attributable to its antioxidant and
nti-inflammatory properties. HDL can prevent LDL oxi-
ation, thereby inhibiting the inflammatory response in-
uced by LDL-derived oxidized lipids (9). Antioxidant
nzymes paraoxinase-1 and platelet-activating factor acetyl-
ydrolase are associated with HDL-C. HDL is known to
nhibit monocyte binding, up-regulate nitric oxide release,
educe monocyte apoptosis induced by cholesterol loading,
reserve monocyte viability by prevention of post-apototic
ecrosis, reduce macrophage excretion of inflammatory
ytokines, and inhibit monocyte attraction (10). Additional
echanisms for protective cancer effects of HDL-C may be
ue to influences on the cell cycle via a mitogen-activated
rotein kinase-dependent pathway or regulation of apopto-
is (4).
lternate Explanations
s low HDL-C simply a marker for smoking, obesity,
nflammation, or hyperinsulinemia, all of which are impli-
ated in the pathogenesis of both atherosclerosis and of
arcinogenesis? Notably, all participants in the ATBC trial
ere smokers (which also lowers HDL-C) (4). Oxidative
nzymes at sites of inflammation can modify apolipoprotein
(
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HDL and Cancer June 22, 2010:2855–7apo) A-I within HDL into a dysfunctional form, impairing
everse cholesterol transport and giving HDL proinflamma-
ory and proatherogenic properties. Inflammation has been
hown to lower HDL-C acutely and long term (11) and
ppears to increase the risk of lung cancer (12). Adiposity
owers HDL-C, increases inflammation and insulin resis-
ance, and increases the risk of several malignancies, includ-
ng prostate and breast cancer (13,14). Insulin is a growth
actor, and high insulin levels have been associated with an
ncreased risk of prostate cancer. Diabetes is associated not
ust with lower HDL-C levels but also dysfunctional HDL
ssociated with glycation (9). Those with metabolic syn-
rome or abdominal adiposity also have increased levels of
nflammatory HDL, which may become less inflammatory
ith weight loss (9). Lifestyle interventions to increase
DL-C may also decrease the risk of cancer. Aerobic
xercise, tobacco cessation, weight loss, and dietary factors
omega-3, omega-6 polyunsaturated fatty acids, monosatu-
ated fatty acids), taken together, can increase HDL-C 2%
o 30%, and a trial of the Mediterranean diet has reported
ecreased cancer risk (14,15).
onsistency of Data
ata are not consistent for the association between HDL-C
nd cancer. Prospective studies that included women found
ow HDL-C levels to be associated with an increased risk of
reast and lung cancer (16). However, the Framingham
tudy revealed no relationship between HDL-C and cancer
isk or noncoronary heart disease mortality (17). On the
ther hand, for cardiovascular disease, HDL-C has consis-
ently been shown to have an independent inverse relation-
hip with cardiovascular disease (18).
roof by Experiment
he gold standard for demonstrating causality is the ran-
omized, controlled clinical trial in which the only variable
hat changes is the exposure. The meta-analysis by Jafri et
l. (2) did not find a relationship between on-treatment
DL-C increases and cancer or any evidence of heteroge-
eity between the various classes of drugs evaluated. In
either the Jafri et al. (2) paper nor this group’s previous
tatin meta-analysis (6) was there evidence of a relationship
etween statins, which modestly increase HDL-C by 3% to
pidemiological Criteria for Causality forDL-C and Cancer or Cardiov scular DiseaseTable 1 Epidemiological Criter a for C usality forHDL-C and Cancer or Cardiovascular Disease
Criteria Cancer Cardiovascular Disease
Exposure predates disease Yes Yes
Dose response Yes Yes
Biological plausibility Yes Yes
Consistency of data No Yes
Alternate explanations excluded No No
Randomized trials No No
DL-C  high-density lipoprotein cholesterol.%, and cancer. aIn addition to lifestyle and statins, several agents increase
DL-C through a variety of mechanisms. The most
ffective agent currently available for increasing HDL-C is
iacin, which increases HDL-C by 20% to 30% (15). In the
oronary Drug Project, men treated with niacin during the
-year trial had a significantly lower mortality rate than
he placebo group after 15 years of follow-up (19). The
ean 1.5-year additional survival in the niacin group was
argely attributable to fewer cardiovascular deaths; cancer
eaths were similar (4.0% vs. 4.4%, p  0.2). Fibrates can
ncrease HDL-C by 10% to 20% (15). Although more
alignancies were initially reported with clofibrate and
emfibrozil in 5-year primary prevention trials, with long-
erm follow-up, there were no significant increases in cancer
ncidence or mortality with gemfibrozil, even with
ollow-up as long as 18 years in the Helsinki Heart Study
20–22). Cancer incidence was similar for both the fenofi-
rate and placebo groups (8%) in the FIELD (Fenofibrate
ntervention and Event Lowering in Diabetes) study (23).
Currently there is insufficient evidence to conclude that
harmacologically increasing HDL-C per se reduces car-
iovascular events. A meta-analysis of randomized trials of
tatins, niacin, and fibrates found that after adjusting for
DL cholesterol changes, pharmacologically increasing the
DL-C level did not reduce the risk of coronary heart
isease events or all-cause death, but did not report on
ancer rates (24). Although the recent Arterial Biology for
he Investigation of the Treatment Effects of Reducing
holesterol 6–HDL and LDL Treatment Strategies trial
ound promising evidence that niacin may induce athero-
clerotic regression as measured by carotid intimal medial
hickness, serious methodological problems, the short du-
ation of the trial, and the lack of reporting end points by
DL-C response limit conclusions regarding the effect of
DL-C increasing per se or of niacin combined with statin
herapy on cardiovascular events (25,26).
Cholesteryl ester transfer protein (CETP) inhibitors and
everal other HDL-C–increasing agents are in develop-
ent. CETP gene deficiency mutations that increase
DL-C levels have been associated with exceptional lon-
evity. This may be due to lower cardiovascular disease
ortality and a healthy survivor effect (absence of 6 major
ge-related diseases, including cancer, and high cognitive
nd physical functioning) rather than a decrease in non-
ardiovascular disease mortality (27). However, a large trial
f the CETP inhibitor torcetrapib, which increased
DL-C by 50%, was stopped early due to excess total
ortality in the torcetrapib group, although similar rates of
ancer were reported. Development of dalcetrapib and
nacetrapib, which do not appear to have the off-target
lood pressure effects of torcetrapib, is ongoing (28). Apo
-I Milano has not moved forward in development. How-
ver, apo A-I mimetics appear promising. The apo A-I
imetic 4F binds oxidized lipids 5 million-fold better than
ative apo A-I, and the removal of oxidized lipids has been
ssociated with resolution of inflammatory changes (9).
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June 22, 2010:2855–7 HDL and Cancereveral ongoing morbidity/mortality trials are evaluating
iacin, fenofibrate, and CETP inhibitors used in combina-
ion with statins. Although the approximately 3- to 5-year
uration of these trials should be adequate for evaluating the
ffects of these agents on cardiovascular disease, the trials
ay not be of sufficient duration to determine anticancer
fficacy.
onclusions
he inverse relationship between HDL-C levels and cancer
r cardiovascular disease meets many criteria supporting a
ausal relationship (Table 1). However, the most important
riteria for causality have not yet been met (lack of alterna-
ive explanations and proof by experiment). Low HDL-C
evels may simply be a reflection of chronic conditions that
ncrease inflammation and insulin resistance, which may
irectly influence atherosclerosis and carcinogenesis. Data
rom ongoing trials are needed before drawing any firm
onclusions regarding the role of niacin or any other
DL-C–increasing drugs in either cardiovascular disease or
ancer prevention. At this time, the evidence best supports
ow HDL-C as a marker for an overall increased risk of
hronic disease. Clearly, individuals with low HDL-C may
xperience particular benefit from lifestyle recommenda-
ions to quit smoking, improve diet, engage in regular
hysical activity, and control weight. Regardless of the
ffects on HDL-C, healthy lifestyle habits have a significant
mpact on the prevention of most of the chronic diseases
ssociated with aging.
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